Kadmon Holdings Company Profile (NASDAQ:KDMN)

About Kadmon Holdings (KDMN)

Kadmon Holdings logoKadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company's other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company's portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson's disease.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: KDMN
  • CUSIP: N/A
Key Metrics:
  • Previous Close: $3.93
  • 50 Day Moving Average: $3.72
  • 200 Day Moving Average: $5.34
  • 52-Week Range: $3.10 - $11.73
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.93
  • P/E Growth: 0.00
  • Market Cap: $168.14M
  • Outstanding Shares: 45,078,000

Analyst Ratings

Consensus Ratings for Kadmon Holdings (NASDAQ:KDMN) (?)
Ratings Breakdown: 2 Hold Ratings, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $14.88 (298.79% upside)

Analysts' Ratings History for Kadmon Holdings (NASDAQ:KDMN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/23/2017Piper Jaffray CompaniesReiterated RatingOverweight$36.10 -> $23.00LowView Rating Details
3/16/2017WBB SecuritiesUpgradeSell -> Hold$3.25MediumView Rating Details
2/1/2017HC WainwrightReiterated RatingBuy$25.00N/AView Rating Details
11/21/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
11/10/2016Jefferies Group LLCReiterated RatingBuy$12.00 -> $10.00N/AView Rating Details
8/22/2016Citigroup IncInitiated CoverageNeutral$12.00N/AView Rating Details
(Data available from 3/23/2015 forward)

Earnings

Earnings History for Kadmon Holdings (NASDAQ:KDMN)
Earnings by Quarter for Kadmon Holdings (NASDAQ:KDMN)
Earnings History by Quarter for Kadmon Holdings (NASDAQ:KDMN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/22/2017        
11/9/2016Q3 2016($0.40)($4.23)$3.90 million$5.70 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Kadmon Holdings (NASDAQ:KDMN)
Current Year EPS Consensus Estimate: $-10.97 EPS
Next Year EPS Consensus Estimate: $-4.03 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.93)($0.93)($0.93)
Q3 20161($0.90)($0.90)($0.90)
Q4 20161($0.57)($0.57)($0.57)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Kadmon Holdings (NASDAQ:KDMN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Kadmon Holdings (NASDAQ:KDMN)
Insider Trades by Quarter for Kadmon Holdings (NASDAQ:KDMN)
Institutional Ownership by Quarter for Kadmon Holdings (NASDAQ:KDMN)
Insider Trades by Quarter for Kadmon Holdings (NASDAQ:KDMN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/13/2017Daniel S LoebMajor ShareholderBuy1,488,095$3.36$4,999,999.20View SEC Filing  
11/16/2016Harlan WaksalCEOBuy2,000$6.37$12,740.00View SEC Filing  
11/14/2016Harlan WaksalCEOBuy2,000$6.79$13,580.00View SEC Filing  
11/11/2016Konstantin PoukalovCFOBuy4,000$5.81$23,240.00View SEC Filing  
9/14/2016Daniel S LoebMajor ShareholderBuy19,611$7.79$152,769.69View SEC Filing  
9/13/2016Daniel S LoebMajor ShareholderBuy68,654$8.33$571,887.82View SEC Filing  
9/6/2016Daniel S LoebMajor ShareholderBuy81,781$9.39$767,923.59View SEC Filing  
8/26/2016Daniel S LoebMajor ShareholderBuy32,916$9.98$328,501.68View SEC Filing  
8/22/2016Daniel S LoebMajor ShareholderBuy11,305$10.00$113,050.00View SEC Filing  
8/15/2016Daniel S LoebMajor ShareholderBuy6,010$9.95$59,799.50View SEC Filing  
8/12/2016Daniel S LoebMajor ShareholderBuy87,529$9.98$873,539.42View SEC Filing  
8/5/2016Daniel S LoebMajor ShareholderBuy66,828$9.94$664,270.32View SEC Filing  
8/3/2016Daniel S LoebMajor ShareholderBuy1,431,996$11.35$16,253,154.60View SEC Filing  
8/1/2016Goldentree Asset Management LpMajor ShareholderBuy208,333$12.00$2,499,996.00View SEC Filing  
7/28/2016Bart M SchwartzDirectorBuy2,000$9.77$19,540.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Kadmon Holdings (NASDAQ:KDMN)
Latest Headlines for Kadmon Holdings (NASDAQ:KDMN)
Source:
DateHeadline
uk.finance.yahoo.com logoKadmon Reports Upcoming Milestones and Fourth Quarter and Full Year 2016 Financial Results (NASDAQ:KDMN)
us.rd.yahoo.com - March 22 at 6:20 PM
News IconKadmon Holdings Inc (KDMN) Rating Increased to Hold at WBB Securities (NASDAQ:KDMN)
www.americanbankingnews.com - March 22 at 10:38 AM
bloomberg.com logoBloomberg Markets: Dave Wilson’s Stock of the Day for March 20 (NASDAQ:KDMN)
www.bloomberg.com - March 21 at 12:11 PM
us.rd.yahoo.com logoCoverage initiated on Kadmon Holdings by Piper Jaffray (NASDAQ:KDMN)
us.rd.yahoo.com - March 14 at 5:19 PM
biz.yahoo.com logoKADMON HOLDINGS, INC. Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Unregistered Sale of Equity S (NASDAQ:KDMN)
biz.yahoo.com - March 9 at 8:25 AM
us.rd.yahoo.com logoKadmon Announces Approximately $23 Million Equity Financing (NASDAQ:KDMN)
us.rd.yahoo.com - March 8 at 6:53 PM
streetinsider.com logoKadmon (KDMN) Issues Encouraging Update on Tesevatinib Phase 2 in NSCLC - StreetInsider.com (NASDAQ:KDMN)
www.streetinsider.com - December 8 at 10:21 AM
streetinsider.com logoKadmon (KDMN) Issues Encouraging Update on Tesevatinib Phase 2 in NSCLC (NASDAQ:KDMN)
www.streetinsider.com - December 7 at 10:28 AM
streetinsider.com logoKadmon (KDMN) Submits ANDA for KD034 (NASDAQ:KDMN)
www.streetinsider.com - December 6 at 10:23 AM
us.rd.yahoo.com logoKadmon Presents Encouraging Data on Tesevatinib in EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases and/or Leptomeningeal Metastases (NASDAQ:KDMN)
us.rd.yahoo.com - December 6 at 10:23 AM
us.rd.yahoo.com logo8:31 am Kadmon Holdings announces data from its ongoing Phase 2 clinical study of tesevatinib for the treatment of epidermal growth factor receptor NSCLC that has metastasized to the brain and/or the leptomeninges (NASDAQ:KDMN)
us.rd.yahoo.com - December 6 at 10:23 AM
businesswire.com logoKadmon Submits Abbreviated New Drug Application Filing for Trientine Hydrochloride to FDA - Business Wire (press release) (NASDAQ:KDMN)
www.businesswire.com - December 5 at 6:22 PM
finance.yahoo.com logo4:01 pm Kadmon Holdings submits ANDA for KD034 - first application submitted to the FDA for a generic trientine hydrochloride product for the treatment of Wilson's disease (NASDAQ:KDMN)
finance.yahoo.com - December 5 at 6:22 PM
finance.yahoo.com logoKadmon Submits Abbreviated New Drug Application Filing for Trientine Hydrochloride to FDA (NASDAQ:KDMN)
finance.yahoo.com - December 5 at 6:22 PM
finance.yahoo.com logoKadmon to Present at the 28th Annual Piper Jaffray Healthcare Conference (NASDAQ:KDMN)
finance.yahoo.com - November 29 at 4:20 PM
businesswire.com logoKadmon to Present Additional Data Demonstrating Tesevatinib Safety for the Treatment of Polycystic Kidney Disease at ... - Business Wire (press release) (NASDAQ:KDMN)
www.businesswire.com - November 21 at 10:56 AM
streetinsider.com logoForm 424B3 Kadmon Holdings, Inc. - StreetInsider.com (NASDAQ:KDMN)
www.streetinsider.com - November 21 at 10:56 AM
streetinsider.com logoForm 424B3 Kadmon Holdings, Inc. (NASDAQ:KDMN)
www.streetinsider.com - November 21 at 10:56 AM
finance.yahoo.com logoKadmon to Present at the Jefferies 2016 London Healthcare Conference (NASDAQ:KDMN)
finance.yahoo.com - November 14 at 9:52 AM
streetinsider.com logoForm 8-K Kadmon Holdings, Inc. For: Nov 09 (NASDAQ:KDMN)
www.streetinsider.com - November 9 at 5:32 PM
businesswire.com logoKadmon Provides Business Update and Reports Third Quarter 2016 Financial Results (NASDAQ:KDMN)
www.businesswire.com - November 9 at 5:32 PM
biz.yahoo.com logoKADMON HOLDINGS, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:KDMN)
biz.yahoo.com - September 14 at 10:01 AM
finance.yahoo.com logoKadmon Reports Financial and Operational Results for the Three and Six Months Ended June 30, 2016 (NASDAQ:KDMN)
finance.yahoo.com - September 7 at 5:56 PM
biz.yahoo.com logoKADMON HOLDINGS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh (NASDAQ:KDMN)
biz.yahoo.com - September 7 at 5:56 PM
investopedia.com logoDan Loeb Owns 17% of Firm Founded by Sam Waksal (KDMN) (NASDAQ:KDMN)
www.investopedia.com - August 29 at 5:44 PM
biz.yahoo.com logoKADMON HOLDINGS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:KDMN)
biz.yahoo.com - August 29 at 5:44 PM
finance.yahoo.com logoKadmon Initiates Phase 2 Clinical Trial Evaluating Tesevatinib in Glioblastoma (NASDAQ:KDMN)
finance.yahoo.com - August 29 at 10:20 AM
finance.yahoo.com logo'Kadmon Offers A Diverse Clinical Pipeline, And Value Optionality,' H.C. Wainwright Says (NASDAQ:KDMN)
finance.yahoo.com - August 22 at 5:51 PM
finance.yahoo.com logoCiti Sees Kadmon's Trials As 'Risky,' Initiates With Neutral Rating (NASDAQ:KDMN)
finance.yahoo.com - August 22 at 5:51 PM
finance.yahoo.com logoDaniel Loeb Discloses Stake in Biopharma Startup Founded by Sam Waskal (NASDAQ:KDMN)
finance.yahoo.com - August 9 at 8:53 AM
finance.yahoo.com logoCoverage initiated on Kadmon Holdings by WBB Securities (NASDAQ:KDMN)
finance.yahoo.com - August 1 at 9:24 AM
247wallst.com logo4 More IPO Hopefuls for Week of August 1 (NASDAQ:KDMN)
247wallst.com - July 31 at 10:39 AM
cnbc.com logoSam Waksal's Kadmon Holdings shares open below offering price in debut (NASDAQ:KDMN)
www.cnbc.com - July 29 at 11:55 AM
bizjournals.com logoShares of drug developer Kadmon slide, worrying investors (NASDAQ:KDMN)
www.bizjournals.com - July 29 at 11:55 AM
wsj.com logo[$$] Redemption on Offer as Disgraced Executive Sam Waksal's Startup Launches IPO (NASDAQ:KDMN)
www.wsj.com - July 26 at 5:48 PM
marketwatch.com logoSam Waksal's Kadmon Holdings prices IPO (NASDAQ:KDMN)
www.marketwatch.com - July 26 at 5:03 PM

Social

Frequently Asked Questions for Kadmon Holdings (NASDAQ:KDMN)

What is Kadmon Holdings' stock symbol?

Kadmon Holdings trades on the NASDAQ under the ticker symbol "KDMN."

How were Kadmon Holdings' earnings last quarter?

Kadmon Holdings Inc (NASDAQ:KDMN) announced its quarterly earnings results on Wednesday, November, 9th. The company reported ($4.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by $3.83. The business earned $5.70 million during the quarter, compared to analyst estimates of $3.90 million. The business's revenue for the quarter was down 49.6% on a year-over-year basis.

When will Kadmon Holdings make its next earnings announcement?

Kadmon Holdings is scheduled to release their next quarterly earnings announcement on Wednesday, March, 22nd 2017.

Where is Kadmon Holdings' stock going? Where will Kadmon Holdings' stock price be in 2017?

6 brokerages have issued 12-month target prices for Kadmon Holdings' stock. Their forecasts range from $3.25 to $25.00. On average, they expect Kadmon Holdings' share price to reach $14.88 in the next twelve months.

What are analysts saying about Kadmon Holdings stock?

Here are some recent quotes from research analysts about Kadmon Holdings stock:

  • 1. According to Zacks Investment Research, "Kadmon Holdings, Inc. is a biopharmaceutical company. It engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. The company is developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. Kadmon Holdings, Inc. is headquartered in New York. " (1/11/2017)
  • 2. Citigroup Inc analysts commented, "We believe investors could find a better de-risked entry point in the next 12–18 months with more data as we see long term upside," analyst Robyn Karnauskas wrote in a note.Related Link: "Kadmon Offers A Diverse Clinical Pipeline, And Value Optionality," H.C. Wainwright Says"While we note 40–100 percent upside if every POC trial works, the stock could trade at $3–$5/sh (50–70 percent downside) if Tesevatinib fails in cancer trials & could trade at cash ($1/sh) if KD-025 also fails due to safety," the analyst continued.Karnauskas noted that the company may face cash crunch beyond first–second quarter of 2017 and they may be at risk of going to capital markets again before majority of data readout in the second half of 2017.That said, the analyst is positive on the Tesevatinib cancer program, as it crosses the blood brain barrier."We see FV of this program at $9/sh (75 percent of our valuation) and model 35 percent probability to brain met NSCLC opportunity ($400 million peak unadjusted) and 25 percent probability to GBM opportunity ($800 million peak unadjusted)," (8/22/2016)

When did Kadmon Holdings IPO?

(KDMN) raised $101 million in an IPO on Wednesday, July 27th 2016. The company issued 5,600,000 shares at $16.00-$20.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and JMP Securities and H.C. Wainwright & Co. were co-managers.

When did the company's lock-up period expire?

Kadmon Holdings' lock-up period expired on Monday, January 23rd. Kadmon Holdings had issued 6,250,000 shares in its IPO on July 27th. The total size of the offering was $75,000,000 based on an initial share price of $12.00. Since the end of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.

Who owns Kadmon Holdings stock?

Kadmon Holdings' stock is owned by a variety of of institutional and retail investors. Top institutional investors include PERCEPTIVE ADVISORS LLC (10.00%), Perceptive Advisors LLC (4.90%), Anchorage Capital Group L.L.C. (0.28%), State Street Corp (0.16%) and Kingdon Capital Management L.L.C. (0.12%). Company insiders that own Kadmon Holdings stock include Bart M Schwartz, Daniel S Loeb, Goldentree Asset Management Lp, Harlan Waksal and Konstantin Poukalov.

Who bought Kadmon Holdings stock? Who is buying Kadmon Holdings stock?

Kadmon Holdings' stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC and State Street Corp. Company insiders that have bought Kadmon Holdings stock in the last two years include Bart M Schwartz, Daniel S Loeb, Goldentree Asset Management Lp, Harlan Waksal and Konstantin Poukalov.

How do I buy Kadmon Holdings stock?

Shares of Kadmon Holdings can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Kadmon Holdings stock cost?

One share of Kadmon Holdings stock can currently be purchased for approximately $3.73.

Kadmon Holdings (KDMN) Chart for Thursday, March, 23, 2017

This page was last updated on 3/23/2017 by MarketBeat.com Staff